Cyclacel Pharmaceuticals, Inc. reported earnings results for the first quarter ended March 31, 2023. For the first quarter, the company reported net loss was USD 5.8 million compared to USD 4.11 million a year ago. Basic loss per share from continuing operations was USD 7.05 compared to USD 6.3 a year ago.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
1.63 USD | +0.02% |
|
+0.64% | -38.94% |
06-26 | Sector Update: Health Care Stocks Softer Late Afternoon | MT |
06-26 | Sector Update: Health Care Stocks Lower in Afternoon Trading | MT |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-38.94% | 2.39M | |
+17.06% | 121B | |
+17.69% | 110B | |
+17.23% | 25.98B | |
-24.36% | 19.27B | |
-18.56% | 15.99B | |
-18.45% | 15.66B | |
-47.75% | 14.5B | |
+57.42% | 14.47B | |
+5.38% | 13.91B |
- Stock Market
- Equities
- CYCC Stock
- News Cyclacel Pharmaceuticals, Inc.
- Cyclacel Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023